AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact
US Draft Drug Legislation Could Complicate Market Entry For Generics And Biosimilars
Build Back Better crumbled last year after Joe Manchin refused to vote for the legislation • Source: Shutterstock 
